C21 · Pharmaceuticals · Global

Phase I small molecule clinical trial share

Global: 62% in 2025.

  • 62% Latest · Global · 2025
  • Annual Release cadence
  • 6 Records · 1 region · 2016–2025

Verified 15 Sep 2026 · 1 publisher · Next period 2026

Over time

Global over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.

Fig 1 · C21 · Global Annual

Phase I small molecule clinical trial share

Global, 2016 to 2025

3 observations · 2016 to 2025

No figure published for these periods

Phase I small molecule clinical trial sharePhase I small molecule clinical trial share. 3 observations from 2016 to 2025, ranging from 60% to 72%. Latest value 62% (2025). % 0 20 40 60 80 2016 2018 2020 2022 2024 72% 62%
Phase I small molecule clinical trial sharePhase I small molecule clinical trial share. 3 observations from 2016 to 2025, ranging from 60% to 72%. Latest value 62% (2025). % 0 20 40 60 80 2016 2018 2020 2022 2024 72% 62%
Phase I small molecule clinical trial sharePhase I small molecule clinical trial share. 3 observations from 2016 to 2025, ranging from 60% to 72%. Latest value 62% (2025). % 0 20 40 60 80 2016 2018 2020 2022 2024 72% 62%
View the underlying data
Phase I small molecule clinical trial share
Period Type Value
2016 Actual 72%
2023 Actual 60%
2025 Actual 62%
Source: IQVIA · percent · CC BY 4.0 · statorigin.org

Every record

6 records · 1 region · 2016–2025. Each period links to its record: the value, its source evidence and original document.

Phase I small molecule clinical trial share: every record, grouped by region, newest first.
Period Value Source Type
Global 6 records
2025 62% IQVIA · 31 Dec 2025
2025 62% IQVIA · 31 Dec 2025
2023 60% IQVIA · 31 Dec 2023
2023 60% IQVIA · 31 Dec 2023
2016 72% IQVIA · 31 Dec 2016
2016 72% IQVIA · 31 Dec 2016

Download this data

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: IQVIA. Licence: CC BY 4.0.

Embed this chart

For automatic sizing and multiple charts, see the JavaScript embed guide.

Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".

<iframe src="https://statorigin.org/embed/pharmaceuticals--phase-i-small-molecule-clinical-trial-share--trend" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Phase I small molecule clinical trial share" loading="lazy"></iframe>
<p><a href="https://statorigin.org/indicators/phase-i-small-molecule-clinical-trial-share">Data: IQVIA via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (IQVIA); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Percentage of Phase I clinical trial starts that evaluate small molecule drugs.
Measure
One slice of Clinical trial starts ( form: share, segment: phase 1 small molecule ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.

Sources · 2 documents

Document Publisher Published Data points
Global R&D Trends 2026 IQVIA — 3
Global R&D Trends 2026 IQVIA — 3

Other slices of clinical trial starts

Frequently asked questions

What is the latest phase I small molecule clinical trial share?

Global: 62% in 2025.

Where does this data come from?

From 2 documents published by IQVIA. Every figure on this page links to its record, which preserves the original source evidence.

How often is it updated?

Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Phase I small molecule clinical trial share [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/phase-i-small-molecule-clinical-trial-share

"Phase I small molecule clinical trial share." StatOrigin, 2026, https://statorigin.org/indicators/phase-i-small-molecule-clinical-trial-share. Accessed 28 Oct. 2026.

StatOrigin. "Phase I small molecule clinical trial share." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/phase-i-small-molecule-clinical-trial-share.

@misc{statorigin_phase_i_small_molecule_clinical_trial_share_2026, title = {Phase I small molecule clinical trial share}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/phase-i-small-molecule-clinical-trial-share}, note = {Data set. Accessed 2026-10-28} }